Physician profile
Edward M Boyle
NPI 1972581437
$618,123.95
in general payments reported to CMS, 2019-2025
9 companies · $40.35 in 2025
The $40.35 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272K · 2020: $251K · 2021: $43K · 2022: $252 · 2023: $51K · 2024: $273 · 2025: $40.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,511.13 |
| Food and Beverage | $997.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clearflow INC. | $597,941.53 | 2019-2023 | Pleuraflow System With Flowglide |
| Medtronic Vascular, INC. | $12,514.20 | 2019-2020 | |
| Boston Scientific Corporation | $6,053.82 | 2019-2024 | Varithena Administration Pack |
| Medtronic, INC. | $1,481.71 | 2021-2024 | Venaseal |
| Janssen Pharmaceuticals, INC | $38.58 | 2019 | |
| Pfizer INC. | $34.31 | 2020-2025 | |
| Kedrion Biopharma, INC. | $24.93 | 2025 | Kedrab, Koate, Gammaked |
| Tactile Systems Technology INC | $20.94 | 2024 | Entre Plus, Flexitouch Plus |
| E.R. Squibb & Sons, L.L.C. | $13.93 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$281,412.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.